BIO-RAD LABORATORIES, INC.
Bio-Rad develops, manufactures, and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics. Its Life Science segment serves research and biopharmaceutical laboratories, manufacturers, quality-control operations, food-safety testing, and science education. Its Clinical Diagnostics segment supplies diagnostic test systems, informatics solutions, test kits, and quality controls to clinical laboratories, typically combining reagents, instruments, and software into integrated testing systems. Bio-Rad makes money by selling products and services through direct sales operations, subsidiaries, distributors, agents, and other intermediaries. Its diagnostics business also generates recurring sales of test kits and consumables used with installed systems. The company serves customers including universities, research institutions, hospitals, diagnostic laboratories, pharmaceutical and biotechnology companies, and food producers. Bio-Rad is headquartered in Hercules, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BIO in the last 30 days.
See all $BIO insider activity →Bio-Rad Laboratories Inc. is set to report Q3 earnings, with analysts expecting EPS of $2.23 and revenue of $649.94M, down from last year. The stock has a neutral rating and $335 mean price target. Investors will focus on progress in transformation, geographic headwinds, and digital PCR traction. Elliott Investment Management holds an activist stake. Last quarter, Bio-Rad beat EPS and revenue estimates.
Bio-Rad Laboratories (BIO) will report Q3'26 earnings on October 22. Analysts expect revenue of 649.94M USD and EPS of 2.23 USD. The announcement is scheduled for 8:00 AM ET.
Bio-Rad Laboratories (NYSE: BIO, BIO.B) launched Foresight Pro chromatography columns packed with Nuvia resins for biomanufacturing. The columns, available in various sizes, are designed for downstream processing in drug development. According to the company, the single-lot packing approach ensures consistency and superior support for biopharma customers.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BIO (BIO-RAD LABORATORIES, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BIO coverage spans earnings, market movers and financial news.
Near-term headwinds versus longer-term margin and growth turnaround will likely drive the post-earnings reaction.
Guidance sets market expectations; actual results will drive price.
Introduction of expanded process‑scale chromatography columns for biomanufacturing.
Positive earnings beat on digital PCR growth may support short‑term upside.
BIO faces dual pressure from sector read-through and execution risk from restructuring, but has a defined cost-cut timeline into 2027.
AlphAI scores every news story that mentions BIO with an AI model for sentiment and relevance, and aggregates insider trades from BIO-RAD LABORATORIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Rad Laboratories Inc. is set to report Q3 earnings, with analysts expecting EPS of $2.23 and revenue of $649.94M, down from last year. The stock has a neutral rating and $335 mean price target. Investors will focus on progress in transformation, geographic headwinds, and digital PCR traction. Elliott Investment Management holds an activist stake. Last quarter, Bio-Rad beat EPS and revenue estimates.
6 min readBio-Rad Laboratories (BIO) will report Q3'26 earnings on October 22. Analysts expect revenue of 649.94M USD and EPS of 2.23 USD. The announcement is scheduled for 8:00 AM ET.
1 min readBio-Rad Laboratories (NYSE: BIO, BIO.B) launched Foresight Pro chromatography columns packed with Nuvia resins for biomanufacturing. The columns, available in various sizes, are designed for downstream processing in drug development. According to the company, the single-lot packing approach ensures consistency and superior support for biopharma customers.
2 min readBio-Rad Laboratories (BIO) shares rose 19.1% in the past month, driven by digital PCR demand and steady Clinical Diagnostics performance. However, Life Science demand remains weak, and the stock trades at a premium valuation. Management expects cost savings to support margins, but investors must weigh execution against subdued end markets. BIO's Digital PCR revenues grew 6% YoY, with instrument revenues up over 20%. Clinical Diagnostics sales were $399M, up 2.6% YoY. Life Science sales fell 4.1%
2 min readDanaher (DHR) reported Q2 2026 results with $6.3B revenue (+5.5% YoY), adj. EPS $1.94 (+8%), and raised full-year 2026 adj. EPS guidance to $8.45–$8.60, but its bioprocessing unit missed expectations. The move pressured Sartorius and Bio-Rad (BIO), which has a $5B strategic stake in Sartorius. Bio-Rad reported Q2 net sales $651M flat YoY and launched a restructuring with $80–$90M pre-tax charges.
4 min readSouth Korean biotech stocks rose as the KOSDAQ rebounded. FromBio surged to the daily upper limit after trading resumed following a 5-for-1 reverse stock split, closing at 3,330 won (+29.82%). It reported 72.2b won revenue in 2025 and an 18.6b won operating loss. Curacle jumped over 18% on hopes of follow-on licensing after its $1.08b MT-103 deal.
6 min readBio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.
6 min readBIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for
6 min readCitigroup has lowered its rating on Bio-Rad Laboratories (BIO) to Neutral and reduced its price target from $375 to $300, citing concerns over the company's process chromatography segment and diagnostic operations in China. Despite this, Bio-Rad recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies, enhancing its capabilities in drug development and monitoring. The article suggests that while Bio-Rad has investment potential, other AI stocks may offer greater upside with less risk.
3 min readThe company doesn't seem like it will generate pops in key fundamentals anytime soon.
3 min read
